|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.705 USD | +3.24% |
|
+0.46% | -7.38% |
| 17/07 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 01/06 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
| Market Cap | 1.28B 1.12B 1.04B 953M 1.8B 124B 1.83B 12.39B 4.87B 60.45B 4.82B 4.72B 209B | P/E 2026 * |
-4.56x | P/E 2027 * | -4.98x |
|---|---|---|---|---|---|
| Enterprise Value | 1.1B 960M 888M 815M 1.54B 106B 1.57B 10.59B 4.16B 51.69B 4.13B 4.03B 178B | EV / Sales 2026 * |
23.4x | EV / Sales 2027 * | 21.7x |
| Free-Float |
74.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +3.24% | ||
| 1 week | +0.46% | ||
| Current month | -4.00% | ||
| 1 month | +2.15% | ||
| 3 months | -12.94% | ||
| 6 months | -1.47% | ||
| Current year | -7.38% |
| 1 week | 9.1 |  | 9.77 |
| 1 month | 9.1 | | 10.89 |
| Current year | 8.55 | | 11.94 |
| 1 year | 5.05 | | 12.41 |
| 3 years | 3.3 | | 13.77 |
| 5 years | 3.3 | | 16.3 |
| 10 years | 0 | | 18.42 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 01/01/2019 | |
Venkat Ramanan
DFI | Director of Finance/CFO | 57 | 01/10/2025 |
Liane Preussner
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 01/07/2020 | |
Peter Chambré
CHM | Chairman | 70 | 01/10/2012 |
Michael Atieh
BRD | Director/Board Member | 72 | 01/07/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/6/26 | Free | Director | 48,000 | 0.0358% | ||
| 16/6/26 | Free | Director | 48,000 | 0.0358% | ||
| 16/6/26 | Free | Director | 48,000 | 0.0358% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.24% | +0.46% | +56.60% | -14.01% | 1.28B | |
| -7.17% | -2.63% | +49.59% | +74.24% | 55.98B | |
| -0.40% | -2.15% | +52.28% | +70.80% | 53.69B | |
| +0.69% | -5.80% | +4.54% | +426.09% | 23.29B | |
| -0.03% | +0.01% | -17.60% | -14.65% | 23.15B | |
| -5.95% | -0.22% | +35.96% | -9.58% | 20.58B | |
| -1.14% | +0.03% | +31.57% | -30.42% | 17.76B | |
| -5.16% | -7.00% | +177.56% | +326.39% | 16.09B | |
| -6.91% | +2.40% | +36.86% | +636.97% | 15.93B | |
| -0.36% | -1.30% | +24.28% | +190.59% | 14B | |
| Average | -2.29% | -1.69% | +45.16% | +165.64% | 24.18B | |
| Weighted average by Cap. | -3.05% | -2.22% | +43.18% | +144.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.04M 41.12M 38.03M 34.89M 66.04M 4.53B 67.19M 453M 178M 2.21B 177M 173M 7.64B | 49.11M 42.93M 39.7M 36.43M 68.95M 4.73B 70.15M 473M 186M 2.31B 184M 180M 7.98B |
| Net income | -278M -243M -225M -207M -391M -26.83B -398M -2.68B -1.05B -13.1B -1.05B -1.02B -45.23B | -278M -243M -225M -207M -391M -26.84B -398M -2.68B -1.05B -13.1B -1.05B -1.02B -45.24B |
| Net Debt | -186M -163M -150M -138M -261M -17.94B -266M -1.79B -705M -8.76B -699M -684M -30.24B | -219M -192M -177M -163M -308M -21.14B -313M -2.12B -831M -10.32B -824M -806M -35.64B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/07/26 | USD 9.725 | +3.46% | 59,478 |
| 16/07/26 | USD 9.400 | -0.74% | 343,292 |
| 15/07/26 | USD 9.470 | +1.28% | 477,292 |
| 14/07/26 | USD 9.350 | +1.30% | 194,610 |
| 13/07/26 | USD 9.230 | -4.65% | 178,908 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMTX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
